<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565747</url>
  </required_header>
  <id_info>
    <org_study_id>DK001</org_study_id>
    <secondary_id>Journal no. 8313-24</secondary_id>
    <secondary_id>Journal no. 461:2007/78029</secondary_id>
    <nct_id>NCT00565747</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for Use in Human IVF</brief_title>
  <acronym>GM-CSF</acronym>
  <official_title>The Effect of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) During in Vitro Culture of Human Embryos on Subsequent Implantation Rates.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Origio A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Origio A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess whether addition of 2 ng/ml GM-CSF into a specific culture medium
      will increase the chance of a pregnancy after in vitro fertilisation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Throughout its development, the embryo is naturally exposed to a large number of cytokines
      and growth factors that are present in the woman's reproductive organs. A growing body of
      evidence indicates that these factors play a physiological role in the regulation of normal
      development of the pre-implanted embryo and that these factors therefore help to increase the
      implantation of the embryo and subsequently ensure optimal development of both foetus and
      placenta. The cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) has been
      shown to be present in the female reproductive organs during early pregnancy in mice, sheep,
      cows and humans.

      2 ng/ml GM-CSF has been proven safe in a previous study presented at the European Society of
      Human Reproduction and Embrylogy (ESHRE) congress 2007 (A. Loft et al. 2007).

      The present investigation (DK001) is to our knowledge the first large prospective randomised
      in vivo study in humans. Previous publications counting one Korean pilotstudy of 154 women
      prospectively randomised between culture medium with and without GM-CSF 2 ng/ml (Kim et al.,
      2001), showing a significant effect of GM-CSF on embryo implantation rate.

      Based on this knowledge we hypothesize that culture of human embryos in the presence of
      GM-CSF will significantly increase the implantation rate also in a larger population.

      This hypothesis is being tested by conducting a multicentre, randomised, parallel group,
      double-blind, placebo-controlled study with adaptive design, performed at 14 study centres.
      Each patient will participate in the study from retrieval of oocytes following standard
      hormonal treatment and until the 12th gestational week. Further a follow-up will be performed
      on pregnancies and children born.

      The test group will include a standard culture medium with 2 ng/ml GM-CSF added from the time
      of insemination, and the control group will be the exact same medium but without any
      additions.

      All procedures are according to standards of the clinic, with applied standard media except
      for the patient randomised study medium which is used for oocyte insemination, embryo culture
      and transfer. Embryo transfer will be performed Day 3.

      An interim analysis has been performed for final sample size calculation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing Implantation Rate Week 7</measure>
    <time_frame>Approximately 5 weeks from oocyte pick-up (corresponding to 7 weeks from ovulation)</time_frame>
    <description>Defined as number of gestational sacs with fetal heart beat, shown by ultrasound in gestational week 7 in percentage of number of embryo transferred.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Top Quality Embryos (TQE´s)</measure>
    <time_frame>3 days from oocyte pick-up</time_frame>
    <description>Number of 4-5 cell embryo at 44 hours,at least 7 cell embryo at 68 hours, maximum 20% fragmentation, equally large blastomeres (less than 25% difference in size),No signs of multinucleation. Calculated in percentage of number of 2 pronuclei (2PN) oocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live Birth</measure>
    <time_frame>Until 7 days after birth</time_frame>
    <description>Subject having at least one live birth. Including a foetus which breathes or shows any other evidence of life after expulsion/extraction from its mother. The definition is independent of the duration of the pregnancy (ICMART/WHO criteria).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1332</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Test culture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Culture with GM-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control culture</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Culture without GM-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test culture</intervention_name>
    <description>A standard culture medium with added GM-CSF (ready-to-use)</description>
    <arm_group_label>Test culture</arm_group_label>
    <other_name>EmbryoGen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control culture</intervention_name>
    <description>The same standard culture medium, but without any additions (ready-to-use)</description>
    <arm_group_label>Control culture</arm_group_label>
    <other_name>EmbryoAssist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The couple or single woman has signed an informed consent form before any
             trial-related activities.

          -  In Vitro Fertilization (IVF) or IntraCytoplasmic Sperm Injection (ICSI) treatment
             indicated

          -  25-39 years of age (both inclusive)

          -  Regular menstrual cycle: 21-35 days (both inclusive)

          -  Women treated with a standard Gonadotropin-Releasing Hormone (GnRH) agonist or
             antagonist protocol and a Follicle Stimulating Hormone (FSH) / human Menopausal
             Gonadotropin (hMG) starting dose between 100 and 300 IU daily.

          -  human Chorionic Gonadotropin (hCG) administration when the leading follicle has a
             calculated diameter of minimum 17 mm, or the day after.

          -  At least 3 follicles with a calculated diameter of ≥ 14 mm at the day of hCG.

        Exclusion Criteria:

          -  The woman has previously participated in the DK001 study.

          -  Use of assisted hatching.

          -  Indication for Testicular Sperm Aspiration (TESA) or Percutaneous Epididymal Sperm
             Aspiration (PESA)

          -  Any medical conditions or genetic disorders prohibiting IVF/ICSI or interfering with
             the interpretation of results of the study (including pre-implantation genetic
             diagnostics).

          -  Use of any investigational drug within 30 days before oocyte retrieval

          -  Any severe chronic disease of relevance for reproductive function.

          -  Oocyte donation patients (donor or recipient).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Søren Ziebe, M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Fertilitetsklinikken afd. 4071</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ciconia Aarhus Privathospital, Fertilitetsklinikken</name>
      <address>
        <city>Aarhus</city>
        <zip>8270</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brædstrup Sygehus; IVF-Klinikken</name>
      <address>
        <city>Brædstrup</city>
        <zip>8740</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Fertilitetsklinikken afd. 4071</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertilitetsklinikken Dronninglund</name>
      <address>
        <city>Dronninglund</city>
        <zip>9330</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVF-SYD</name>
      <address>
        <city>Fredericia</city>
        <zip>7000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital, Fertilitetsklinikken G114F</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holbæk Sygehus, Fertilitetsklinikken</name>
      <address>
        <city>Holbæk</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital; Fertilitetsklinikken afd. 455</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitets Hospital, Fertilitetsklinikken</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Skive, Fertilitetsklinikken</name>
      <address>
        <city>Skive</city>
        <zip>7800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maigaard Fertilitetsklinik</name>
      <address>
        <city>Århus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVF Kliniken Öresund</name>
      <address>
        <city>Malmö</city>
        <zip>205 12</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge, Fertilitetsenheten K59</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproduktionscentrum</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2007</study_first_submitted>
  <study_first_submitted_qc>November 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <results_first_submitted>May 7, 2013</results_first_submitted>
  <results_first_submitted_qc>September 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2013</results_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GM-CSF</keyword>
  <keyword>infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall recruitment period: October 2007 until August 2010. Patients were recruited at both public and private IVF clinics</recruitment_details>
      <pre_assignment_details>Patients with informed consent but where it turned out that the inclusion/exclusion criteria were not fulfilled before assignment to groups, were excluded from the per-protocol (PP) analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Test Culture</title>
          <description>Culture with 2 ng/ml GM-CSF</description>
        </group>
        <group group_id="P2">
          <title>Control Culture</title>
          <description>Culture without GM-CSF</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="654"/>
                <participants group_id="P2" count="678"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="587">Completed with an embryo transfer</participants>
                <participants group_id="P2" count="605">Completed with an embryo transfer</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No embryo transfer</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Culture</title>
          <description>Culture with 2 ng/ml GM-CSF</description>
        </group>
        <group group_id="B2">
          <title>Control Culture</title>
          <description>Culture without GM-CSF</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="654"/>
            <count group_id="B2" value="678"/>
            <count group_id="B3" value="1332"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="3.7"/>
                    <measurement group_id="B2" value="32.4" spread="3.8"/>
                    <measurement group_id="B3" value="32.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="654"/>
                    <measurement group_id="B2" value="678"/>
                    <measurement group_id="B3" value="1332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="610"/>
                    <measurement group_id="B2" value="635"/>
                    <measurement group_id="B3" value="1245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ongoing Implantation Rate Week 7</title>
        <description>Defined as number of gestational sacs with fetal heart beat, shown by ultrasound in gestational week 7 in percentage of number of embryo transferred.</description>
        <time_frame>Approximately 5 weeks from oocyte pick-up (corresponding to 7 weeks from ovulation)</time_frame>
        <population>PP-population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Culture</title>
            <description>Culture with 2 ng/ml GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Control Culture</title>
            <description>Culture without GM-CSF</description>
          </group>
        </group_list>
        <measure>
          <title>Ongoing Implantation Rate Week 7</title>
          <description>Defined as number of gestational sacs with fetal heart beat, shown by ultrasound in gestational week 7 in percentage of number of embryo transferred.</description>
          <population>PP-population</population>
          <units>percentage of transferred embryos</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="564"/>
                <count group_id="O2" value="585"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Embryos transferred</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="838"/>
                <count group_id="O2" value="882"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Top Quality Embryos (TQE´s)</title>
        <description>Number of 4-5 cell embryo at 44 hours,at least 7 cell embryo at 68 hours, maximum 20% fragmentation, equally large blastomeres (less than 25% difference in size),No signs of multinucleation. Calculated in percentage of number of 2 pronuclei (2PN) oocytes.</description>
        <time_frame>3 days from oocyte pick-up</time_frame>
        <population>PP-population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Culture</title>
            <description>Culture with 2 ng/ml GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Control Culture</title>
            <description>Culture without GM-CSF</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Top Quality Embryos (TQE´s)</title>
          <description>Number of 4-5 cell embryo at 44 hours,at least 7 cell embryo at 68 hours, maximum 20% fragmentation, equally large blastomeres (less than 25% difference in size),No signs of multinucleation. Calculated in percentage of number of 2 pronuclei (2PN) oocytes.</description>
          <population>PP-population</population>
          <units>percentage of 2PN's</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="564"/>
                <count group_id="O2" value="585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Live Birth</title>
        <description>Subject having at least one live birth. Including a foetus which breathes or shows any other evidence of life after expulsion/extraction from its mother. The definition is independent of the duration of the pregnancy (ICMART/WHO criteria).</description>
        <time_frame>Until 7 days after birth</time_frame>
        <population>PP-population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Culture</title>
            <description>Culture with 2 ng/ml GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Control Culture</title>
            <description>Culture without GM-CSF</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth</title>
          <description>Subject having at least one live birth. Including a foetus which breathes or shows any other evidence of life after expulsion/extraction from its mother. The definition is independent of the duration of the pregnancy (ICMART/WHO criteria).</description>
          <population>PP-population</population>
          <units>percentage of transfer patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="564"/>
                <count group_id="O2" value="585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Test Culture</title>
          <description>Culture with 2 ng/ml GM-CSF</description>
        </group>
        <group group_id="E2">
          <title>Control Culture</title>
          <description>Culture without GM-CSF</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="654"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="678"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine retension, haematuria and cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="654"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="678"/>
              </event>
              <event>
                <sub_title>Foetus or child born with malformations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="654"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="678"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Miscarriage (missed abortion)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="654"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="678"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal haemorrhage after oocyte pick-up.</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="654"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="678"/>
              </event>
              <event>
                <sub_title>Ovarian Hyperstimulation Syndrome</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="654"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="678"/>
              </event>
              <event>
                <sub_title>Ovarian torsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="654"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="678"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="654"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="678"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="654"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="678"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Miscarriage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="654"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="678"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Confidentiality until publication of the main results of the study</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Origio A/S</organization>
      <phone>+45 46790200</phone>
      <email>sbendz@origio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

